Moleculin Biotech, Inc COVID-19 potential

Nano cap Moleculin Biotech (MBRX +47.5%) rallies on a healthy 15x surge in volume in reaction to its agreement with the University of Texas Medical Branch at Galveston (UTMB) to conduct research on the company's line-up of molecular inhibitors, including lead candidate WP1122, to assess their antiviral properties against a range of viruses, including coronavirus.

WP1122 is a prodrug of 2-DG (2-deoxy-D-glucose), a dual decoy of simple sugar glucose and mannose (a kind of sugar related to glucose) that may be effective in treating viral infection. Emerging research on the role of glucose and mannose metabolism in viral activity has apparently been encouraging.

Under the terms of the collaboration, Moleculin will supply WP1122, related inhibitors and technical support while UTMB will conduct testing in a range of viral disease models, including COVID-19.
Source seekingalpha



Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.